BCAX Logo

Bicara Therapeutics Inc. Common Stock (BCAX) 

NASDAQ
Market Cap
$1.32B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
12 of 776
Rank in Industry
11 of 433

Largest Insider Buys in Sector

BCAX Stock Price History Chart

BCAX Stock Performance

About Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Insider Activity of Bicara Therapeutics Inc. Common Stock

Over the last 12 months, insiders at Bicara Therapeutics Inc. Common Stock have bought $33.62M and sold $0 worth of Bicara Therapeutics Inc. Common Stock stock.

On average, over the past 5 years, insiders at Bicara Therapeutics Inc. Common Stock have bought $33.62M and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $824.85M. Flynn James E (Possible Members of 10% Group) — $23.94M.

The last purchase of 35,000 shares for transaction amount of $630,000 was made by Flynn James E (Possible Members of 10% Group) on 2024‑09‑17.

List of Insider Buy and Sell Transactions, Bicara Therapeutics Inc. Common Stock

2024-09-17PurchasePossible Members of 10% Group
35,000
0.045%
$18.00$630,000-12.49%
2024-09-16Purchase
1.83M
2.6517%
$18.00$32.99M-6.73%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.